Results 101 to 110 of about 9,061 (176)

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

Journal of Comparative Effectiveness Research
Aim: Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based on data from
Stephen Chia, Jie Li, Fei Ma, Daniel Stellato, Andriy Danyliv, Ilia Ferrusi, Huilin Hu, Murat Akdere, Andreas Makris   +8 more
doaj   +1 more source

Cyclin-dependent kinase inhibitor abemaciclib-induced cutaneous responses mediated by inflammation

Abemaciclib is a cyclin-dependent kinase (CDK) enzyme inhibitor approved by the FDA for advanced and metastatic breast cancer therapy. Abemaciclib has caused someadverse reactions, such as dermatitis and skin reactions; however, the underlying cellular ...
KENANOĞLU, Mahmut Fırat, ÖZHAN, Gül, Camli, Ozce Pala, Boran, TUĞÇE   +3 more
core   +1 more source

Inhibition of CDK/Cyclin-phospho-Rb signaling by amebaciclib may have an antitumor effect against uterine leiomyosarcoma. [PDF]

Signal Transduct Target Ther
Hayashi T, Muto M, Konishi I.
europepmc   +1 more source

Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study. [PDF]

Acta Oncol
Rosander C, Larsson K, Karlsson P.
europepmc   +1 more source

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE). [PDF]

ESMO Real World Data Digit Oncol
Abdallah H, Owoseni Y, Baraka B, Ghose A, Konstantis, Muhammad R, Maniam A, Atsumi N, Horne S, Nazir A, Mooney L, Nazeer F, McAvan L, Abraham M, Bean E, Morgan D, Langford G, Morris E, Daniels E, Pravinkumar R, Mohammed S, Raza S, Blair C, Khan R, Tsalic M, Kussaibati R, Douglas R, Panagiotis K, Waters S, Smith J, Papadimitraki E, Michie C, Wilson C, Ayodele O.   +33 more
europepmc   +1 more source

Real-World Safety Profile of Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer. [PDF]

Cancers (Basel)
Macedo MP, Sousa ID, Tavares NT.
europepmc   +1 more source

BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer. [PDF]

Biomedicines
Thoidingjam S, Sriramulu S, Haider Muratoglu A, Hede-Sakhardande R, Ghosh S, Davis AJ, Brown SL, Siddiqui F, Movsas B, Speers C, Nyati S.   +10 more
europepmc   +1 more source

Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. [PDF]

Neuro Oncol
Surender S, Haeusser LA, Kuhlburger L, Tsiami F, Dogan NO, Maise L, Nahnsen S, Beck S, Merk DJ, Tabatabai G.   +9 more
europepmc   +1 more source

Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in <i>MYCN</i>-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study. [PDF]

Int J Mol Sci
Çerçi B, Karahan Hİ, Soyöz M, Pehlivan M, Pirim İ.   +4 more
europepmc   +1 more source

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). [PDF]

Breast Cancer Res Treat
Nishimura M, Kogawa T, Sugiyama K, Ozaki Y, Tanabe Y, Funasaka C, Kurozumi S, Yoshimura A, Iwasa T, Sakai H, Morita M, Watanabe S, Fujii T, Yamamoto M, Tsuji Y, Terada M, Ota T, Tokunaga S, Shimokawa M, Takano T.   +19 more
europepmc   +1 more source